EMvision Medical Devices: Half Yearly Report and Accounts
Filed with ASX · · 20 pages · English
The loss for the Company for the half-year after providing for income tax amounted to $3,967,663 (31 Dec 2024: $3,571,869). The higher loss reflects increased operating expenses during the period, including an increase in share-based payment expenses to $1,269,189 (31 Dec 2024: $465,711). While this is a non-cash item, it materially increased expenses compared to the prior period. Adjusting for th
EMvision Medical Devices Ltd. on 6ix
In the deck
Earlier from EMvision Medical Devices
- Quarterly Activities/Appendix 4C Cash Flow Report
- Strong emu Clinical Trial & Program Progress
- First Responder Aeromedical Study Commences
- Oversubscribed SPP Raises $2.0M
- Oversubscribed SPP To Close Early
Later from EMvision Medical Devices
- EMVision Medical Devices to Present at Australia Investor Day February 26th
- S&P DJI Announces March 2026 Quarterly Rebalance
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- $3.8m R&D Rebate Received & Overseas Finding Approved
- emu Pivotal Trial Expansion Adds Acute Ischaemia Detection
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices